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Aim To investigate the safety and efficacy of bupropion sustained release (bupropion SR)
in promoting abstinence from smoking in subjects with cardiovascular disease (CVD).
Methods Six hundred twenty-nine subjects with CVD who smoked ≥10 cigarettes/day
were randomised in a double-blind, multicentre study to receive bupropion SR
(150 mg twice daily) or placebo for 7 weeks, with a follow-up of 52 weeks. Primary
efficacy endpoint: continuous abstinence from smoking from weeks 4 to 7. Secondary
endpoints: continuous abstinence (weeks 4–12, 4–26 and 4–52) and weekly point
prevalence abstinence. All participants received brief motivational support. Safety
was evaluated throughout the study.
Results Continuous smoking abstinence rates from weeks 4 to 7 were significantly
higher in subjects receiving bupropion SR compared with placebo (43 vs. 19%, odds
ratio [OR]=3.27, 95% confidence interval [CI] 2.24–4.84; P<0.001). Continuous absti-
nence rates from weeks 4 to 26 and 4 to 52 continued to be more than double for
bupropion SR compared with placebo (27 vs. 11%; 22 vs. 9%, P<0.001). Weekly point
prevalence abstinence was significantly higher for participants who received bupro-
pion SR compared with placebo at weeks 3, 7, 26 and 52 (P<0.001). In both groups,
there were no clinically significant changes in blood pressure and heart rate through-
out the treatment phase. Overall, 6% of the participants (n36) discontinued study
medication due to an adverse event (bupropion SR, n17; placebo, n19).
Conclusions After 7 weeks of bupropion SR treatment, more than twice as many
smokers with CVD had quit smoking at 1 year compared with placebo. The safety profile
of bupropion SR was similar to that previously observed in general smoking populations.
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Introduction
Strong, consistent epidemiological evidence links
cigarette smoking to increased cardiovascular dis-
ease (CVD) morbidity and mortality.1,2 In the devel-
oped world, CVD (most often ischaemic heart
disease) is the most common smoking-related cause
of death, with 25% of deaths in the 35–69 years age
group being due to tobacco.3 It has been recognised
for some time that mortality levels are significantly
higher among smokers who have experienced a
myocardial infarction and continue to smoke, com-
pared with those who quit.4 Furthermore, the risk
of a coronary event declines rapidly after stopping
smoking, and after 2–3 years of abstinence the
risk of such an event is similar to that for subjects
who have never smoked.5–7 For this reason, the
Joint British Recommendations on Prevention of
Coronary Heart Disease in Clinical Practice state
that stopping smoking is one of the primary lifestyle
options for reducing the risk of coronary heart
disease.8
Bupropion sustained release (bupropion SR) is a
non-nicotine-based treatment for use in smoking
cessation. Controlled clinical studies involving
approximately 8000 subjects receiving bupropion
SR have now demonstrated the efficacy and
tolerability of this agent.9–13 This efficacy is
acknowledged in smoking cessation guidelines14–16
and the National Institute for Clinical Excellence
has recently recommended its use in smoking ces-
sation.17 Bupropion SR is effective in smokers who
may be considered particularly refractory to treat-
ment.11,18 In addition, meta-analyses suggest that
the efficacy, tolerability and safety of bupropion
SR are unaffected by a previous history of serious
conditions such as alcoholism and major depres-
sion.19 However, there have been no clinical
studies carried out to date that have assessed
bupropion SR as an aid to smoking cessation in
subjects with CVD. Smokers who have survived
a cardiac event but not quit smoking may be more
nicotine dependent or face more barriers to
quitting than other smokers.
We conducted a double-blind, multicentre, ran-
domised study to assess the efficacy and safety of
bupropion SR in subjects with smoking-related CVD.
Methods
Participants
We enrolled adults who smoked an average of
≥10 cigarettes/day during the previous 12 months
and who had not made a serious attempt to stop
smoking using nicotine replacement therapy during
the previous 3 months. Subjects had not made a
quit attempt lasting >3 months during the previous
year. All participants were motivated to stop smok-
ing and had at least one of the following cardiovas-
cular conditions: myocardial infarction >3 months
ago, interventional cardiac procedure (excluding
valve replacement) >3 months ago, stable angina
pectoris, peripheral vascular disease (excluding
varicose veins and current deep vein thrombosis)
or congestive heart failure (NYHA Class I or II).
Subjects with at least one of these conditions, with
or without hypertension, were eligible. However,
hypertension had to be controlled (i.e. <160/
100 mmHg; baseline systolic and diastolic values,
respectively) by diet, exercise, or medication.
Subjects were excluded if they had a predisposi-
tion for seizure; had a current diagnosis of severe
renal, hepatic, haematological, pulmonary or
neurological disease; or had a history or current
diagnosis of bulimia or anorexia nervosa. Subjects
were also excluded if they had an acute or chronic
medical condition likely to impair drug absorption,
distribution, metabolism or excretion; had a history
or current diagnosis of panic disorder, psychosis, or
bipolar disorder; or were depressed.
The protocol was approved by the appropriate
Independent Ethics Committee or Institutional
Review Board and participants provided written
informed consent.
Interventions
We performed a multicentre, randomised, double-
blind, placebo-controlled study in subjects from 28
centres across 10 countries.
The study consisted of a 1- to 2-week screening/
baseline phase, a 7-week treatment phase and
follow-up at 3, 6 and 12 months. Subjects set
a target quit date for >7 but ≤14 days after base-
line assessment. At baseline, smoking history
and cardiovascular diagnoses were collected, and
expiratory carbon monoxide levels were measured
using a Bedfont Smokerlyser monitor. Participants
were also weighed and two questionnaires (the
Fagerstro¨m Tolerance Questionnaire20,21 and a
Smoking Assessment Questionnaire) were com-
pleted. Participants were then randomised in a 1:1
ratio to receive either bupropion SR (150 mg/day on
days 1–3; 150 mg twice daily on days 4–49) or
placebo during the 7-week treatment phase.
Subjects were contacted by telephone 1 day
before their target quit date and reminded that
they were due to stop smoking the following day.
Three days after this date, subjects were again
Bupropion SR in smokers with cardiovascular disease 947
contacted to provide motivational support. Partici-
pants recorded their cigarette consumption
(number of cigarettes per day) on a diary card
and visited the clinic each week throughout
the treatment phase. At each clinic visit, subjects
were weighed, vital signs and expiratory carbon
monoxide levels measured and brief motivational
support (10–15 min) was given. At week 7, the
Smoking Assessment Questionnaire was completed.
During follow-up, subjects were contacted at
monthly intervals to encourage abstinence from
smoking and prevent relapse. At weeks 12, 26 and
52, subjects were weighed, expiratory carbon mon-
oxide levels and vital signs were measured and brief
motivational support given. Subjects who withdrew
or missed a clinic visit were assumed to be smoking.
Primary outcomes
The primary outcome was defined as continuous
abstinence from smoking for a 4-week period from
the beginning of week 4 of the treatment phase.
Continuous abstinence was assessed by the investi-
gator and confirmed by the subject's self-report of
not smoking and an expiratory carbon monoxide
level <10 ppm. Subjects with missing investigator
assessments were assumed to be smokers at that
visit.
Secondary outcomes
Secondary outcomes of efficacy included con-
tinuous abstinence from smoking from week 4 to
weeks 12, 26 and 52. In addition, weekly point
prevalence abstinence (abstinence from smoking
for the previous 7-day period) was assessed during
the treatment and follow-up phase.
Change in body weight relative to baseline was
assessed at the end of the treatment phase (week
7) and at weeks 26 and 52 of the follow-up phase.
At week 7, subjects were asked to evaluate
their experience with the study medication, and
whether they would recommend it to other smokers
(Smoking Assessment Questionnaire).
Safety
Vital signs were recorded throughout the study, and
adverse events were recorded throughout the
treatment phase and up to week 9. All serious
adverse events were collected throughout the
treatment phase, after which only serious adverse
events related to study medication were recorded.
Statistics
In the study of Tashkin et al.,11 which examined
smokers considered refractory to treatment, the
4-week continuous abstinence rate was 15% for
subjects receiving placebo. We considered a 10%
increase in the continuous abstinence rate for sub-
jects receiving bupropion SR to be clinically rel-
evant. Therefore, we assumed that 15% of subjects
receiving placebo and 25% of subjects receiving
bupropion SR would remain continuously abstinent
during weeks 4–7 of the current study. With 620
participants randomised 1:1, the study would have
at least 85% power to detect this difference at the
two-sided 5% level of significance and detect a
difference assuming that 5% of the subjects ran-
domised to placebo and 12% of those randomised to
bupropion SR, remained continuously abstinent at
6 months.
Data were analysed using sas® (v.6.12) statistical
software. For continuous abstinence data, compari-
son of the treatment groups was performed using an
exact test according to Gart and Cox22,23 stratified
by country. For point prevalence abstinence, the
treatment groups were compared using the exact
test. Change in weight relative to baseline was
compared by analysis of covariance including
terms for treatment, centre, gender and abstention
status, with baseline weight as a covariate.
Results
Participant characteristics
Six hundred and sixty-nine potential subjects were
screened, and 629 participants were enrolled, of
whom 626 received at least one dose of study
medication (intent-to-treat population; n313 in
each group) [Fig. 1]. After 52 weeks, 120 (38%)
patients receiving bupropion SR and 155 (50%)
receiving placebo had prematurely discontinued
treatment.
Treatment groups were comparable in terms of
age, gender, race and smoking history (Table 1).
This population of chronic smokers had a mean
pack-year history of 49.6 years and a mean
Fagerstro¨m Tolerance Questionnaire score of 6.6.
Most subjects (85%) had made at least one previous
attempt to stop smoking, and 31% had made ≥5
previous cessation attempts. Overall, 27% of sub-
jects had chronic obstructive pulmonary disease
and/or diabetes and the incidence of these
conditions was similar for both treatment groups
(Table 1). Subjects entering the study presented
with a range of cardiovascular diagnoses and
included 306 (49%) who had previously experienced
a myocardial infarction (Fig. 2). Patients must have
had at least one of the following to be eligible for
the study (±controlled hypertension): myocardial
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infarction (>3 months ago), interventional cardiac
procedure (>3 months ago), stable angina, periph-
eral vascular disease (excluding varicose veins and
current deep vein thrombosis) or congestive heart
failure (class I or II).
Primary outcomes
A significantly higher percentage of subjects
receiving bupropion SR achieved continuous
abstinence from smoking for weeks 4–7 (Fig. 3)
compared with those receiving placebo—43% (134/
313) of subjects receiving bupropion SR remained
abstinent, compared with 19% (61/313) of those
receiving placebo (P<0.001, odds ratio [OR] 3.27;
95% confidence interval [CI] 2.24–4.84).
Secondary outcomes
Bupropion SR treatment resulted in consistently
higher rates of abstinence than placebo. At week
26, 27% (84/313) of subjects receiving bupropion SR
remained abstinent, compared with 11% (34/313)
of those receiving placebo (P<0.001). At week 52
the corresponding values were 22% (68/313) and 9%
(29/313) for bupropion SR vs. placebo, respectively
(P<0.001).
In both treatment groups, subjects with CVD
and chronic obstructive pulmonary disease and/or
diabetes had similar continuous abstinence rates
for weeks 4–52 compared with CVD only (18 and
15%, respectively).
Point prevalence abstinence
Weekly point prevalence abstinence for the bupro-
pion SR group remained more than double that of
the placebo group throughout the study. Statistical
analysis revealed significantly greater weekly point
prevalence abstinence (P<0.001) in participants
receiving bupropion SR compared with placebo at
all prespecified time points (Fig. 4).
Fig. 1 Participant flow diagram.
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At weeks 7 and 26 the odds of not having smoked
during the preceding week were almost four times
higher for bupropion SR-treated subjects compared
with those receiving placebo (OR 3.96, 95% CI 2.74–
5.79; OR 3.85, 95% CI 2.50–6.03, respectively).
Body weight
During the treatment phase, subjects receiving
bupropion SR who had abstained from smoking
from the beginning of week 4 to the end of week 7
gained an average of 1.15 kg less weight than those
receiving placebo (95% CI 0.46–1.83 kg). However,
participants who remained abstinent at week 52
experienced a similar overall gain in weight,
regardless of treatment group, with bupropion SR-
treated subjects gaining an average of 0.9 kg more
at week 52 (95% CI −1.19 to 2.80 kg).
Smoking assessment questionnaire
Responses to the Smoking Assessment Question-
naire were more positive for bupropion SR than
placebo in four of the seven questions (Fig. 5). At
Table 1 Baseline characteristics
Bupropion SR (n=313) Placebo (n=313)
Age [mean (SD)] 55.6 (9.2) 55.1 (9.0)
Female 26% 21%
Caucasian 98% 99%
Age started smoking [mean (SD)] 17.1 (4.9) 16.8 (4.3)
Pack years [mean (SD)] 49.8 (27.1) 49.3 (23.7)
Cigarettes per day [mean (SD)] 25.2 (12.2) 25.6 (11.7)
Fagerstro¨m Tolerance Questionnaire score [mean (SD)]a 6.5 (2.0) 6.6 (2.0)
Quit attempts
Previous number of attempts [mean (SD)] 6.1 (12.3) 4.7 (8.2)
Used willpower [number of subjects (%)] 221 (71) 208 (66)
Used nicotine replacement therapy [number of subjects (%)] 135 (43) 132 (42)
Comorbid conditions
Chronic obstructive pulmonary disease [number of subjects (%)] 54 (17) 41 (13)
Diabetes [number of subjects (%)] 44 (14) 43 (14)
Pack year history=([number of years smoking]×[number of cigarettes per day])/20.
an263 for bupropion SR and placebo.
Fig. 2 Cardiovascular diagnoses at baseline for all subjects (n626).
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the end of treatment, 61% of subjects in the
bupropion SR group considered that the urge to
smoke was not a problem, compared with 37% of
those receiving placebo. Both treatment groups
generally felt that side effects were not a problem.
However, 28% of subjects receiving bupropion SR
felt that altered sleeping patterns were a problem
compared with 16% for placebo.
In total, 89% of subjects in the bupropion SR
group stated that they would recommend their
study medication to other smokers, compared with
72% of those in the placebo group.
Fig. 3 Continuous abstinence during the treatment and follow-up phases.
Fig. 4 Weekly point prevalence abstinence during the treatment and follow-up phases.
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Safety
A total of 64% (201/313) of subjects receiving
bupropion SR and 58% (181/313) of those receiving
placebo experienced at least one adverse event
whilst on treatment (and 2 weeks thereafter). The
most frequently reported events were insomnia
(24% bupropion SR; 12% placebo) and dry mouth
(18% bupropion SR; 10% placebo) [Table 2]. The
frequency with which these events were reported
was similar regardless of disease group (CVD or CVD
and chronic obstructive pulmonary disease and/or
diabetes) or age.
In total, 38 subjects (6%) reported cardiovascular
adverse events (bupropion SR n24; placebo
n14). The most common were angina pectoris
(bupropion SR n7; placebo n4), hypertension
(bupropion SR n2; placebo n3), and palpitations
(bupropion SR n4; placebo n1).
A total of 36 participants (6%) discontinued from
the study due to an adverse event (bupropion SR
n17 [5%]; placebo n19 [6%]) (Table 2). Eight
participants experienced a total of nine serious
adverse events during the study, and five of these
occurred during treatment (bupropion SR n5, pla-
cebo n0). Three events were considered to be
possibly a worsening of a preexisting condition,
angina pectoris (n2) and vascular disease (n1).
Glaucoma (n1) and lupus erythematodes dissemi-
natus (n1) were also reported. Only one of these
events was considered possibly related to study
treatment (lupus), and none led to discontinuation
of study medication. One event (worsening of con-
gestive heart failure) occurred following the
screening visit, prior to the receipt of study
medication, in a patient ultimately randomised to
placebo.
Within a week of finishing treatment, three
serious adverse events were reported. One subject
had received bupropion SR during the treatment
phase, and the event (vestibular disorder) was
not considered to be related to study medication.
The two remaining events (chest pain, dyspnoea)
were reported by one subject who had received
placebo.
Fig. 5 Smoking Assessment Questionnaire responses at the end of treatment.
Table 2 Summary of adverse events
Bupropion SR (n=313) Placebo (n=313)
Adverse event
Insomnia 75 (24) 37 (12)
Dry mouth 55 (18) 31 (10)
Nausea 40 (13) 19 (6)
Headache 35 (11) 34 (11)
Dizziness 24 (8) 17 (5)
Constipation 16 (5) 4 (1)
Sweating 16 (5) 10 (3)
Insomnia 4 (1) 1 (<1)
Nausea 5 (2) 3 (<1)
Headache 3 (<1) 4 (1)
Dizziness 2 (<1) 3 (<1)
Abdominal pain 1 (<1) 3 (<1)
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There were four deaths during the study (two
patients receiving bupropion SR and two receiving
placebo), and none was related to study medica-
tion. All deaths occurred during the follow-up
phase and occurred between 66 and 313 days after
the last dose of study medication.
Vital signs
No overall treatment effect was observed in sys-
tolic and diastolic blood pressure and heart rate
(mean changes in beats per minute from baseline to
week 7 were −2.15 and −0.80, for bupropion SR and
placebo, respectively). No clinically significant
change in vital signs was seen for either treatment
during the follow-up phase to week 52. At week 52,
the mean change from baseline in systolic blood
pressure with bupropion SR and placebo was +1.5
and +3.5 mmHg, respectively. The corresponding
change from baseline in diastolic blood pressure
with bupropion SR was +0.7 mmHg compared with
+2.2 mmHg for placebo.
Discussion
We have conducted the first prospective study of
non-nicotine pharmacotherapy in a population of
persistent smokers with CVD, nearly half of whom
had experienced a myocardial infarction >3
months previously. At 6 and 12 months after
beginning treatment, subjects who had received
bupropion SR were significantly more likely to
have successfully stopped smoking than those
receiving placebo. Bupropion SR was well toler-
ated and the safety profile was more favour-
able than expected for a study population of this
type.
Smokers in the present study were recruited in
the settings of primary and secondary/tertiary care
in addition to smoking cessation clinics. Thus, these
smokers were clearly different from smokers
recruited to previous studies of bupropion SR con-
ducted in subjects recruited from a general smok-
ing population, with the exception of one study
carried out in patients with chronic obstructive
pulmonary disease.11 All patients were diagnosed
with a cardiovascular condition, over one-quarter
were also diagnosed with chronic obstructive pul-
monary disease and/or diabetes, and most (96%)
were taking concomitant medications. Further-
more, the mean pack year history (49.6 years) and
mean number of quit attempts (5.4) were higher
than observed in previous bupropion SR studies in
general smoking populations.9,10 However, this
smoking profile was similar to that of subjects with
chronic obstructive pulmonary disease recruited in
a more recent bupropion SR study11 in that both of
these populations were older, less healthy, had
smoked for a longer period of time and made
more quit attempts than participants in earlier
studies.9,10 In addition, both study populations
comprised subjects with chronic smoking histories
who continued the habit despite developing
smoking-related diseases, and who may therefore
be particularly refractory to smoking-cessation
treatment.
Bupropion SR was significantly more effective
than placebo as an aid to smoking cessation for
smokers with CVD and the odds of being con-
tinuously abstinent by week 4 and maintaining this
until weeks 26 and 52, were around three times
greater for bupropion SR. Weekly point prevalence
analysis (continuous abstinence 7 days prior to
each clinic visit) confirmed these findings, with
rates being more than double throughout the
study for bupropion SR compared with placebo.
Notably, abstinence rates were comparable to
those found in previous clinical studies in a gen-
eral smoking population9,10,12 and to that esti-
mated in a recent meta-analysis conducted by the
National Institute for Clinical Excellence. This
meta-analysis reported that treatment with bu-
propion gave an OR of 2.16 (95% CI 1.51–3.10) for
continuous abstinence compared to placebo.17
The institute estimated that nicotine replacement
therapy gave an OR of 1.69 (95% CI 1.57–1.82)
compared to placebo.17
The motivational support provided during this
study was minimal (10–15 min sessions with existing
clinical staff) and similar to that provided in previ-
ous trials of bupropion SR. Furthermore, the weight
gain in subjects treated with bupropion SR was
noticeably less than that in the placebo group while
they were receiving treatment. This finding is sig-
nificant because individuals often start smoking
again if they gain weight,24 and although the
benefit appears to be short term, bupropion SR may
help to alleviate this.
Responses to the Smoking Assessment Question-
naire add further support to these central efficacy
findings. More than half of subjects confirmed
that the urge to smoke was not a problem with
bupropion SR, and the majority stated they
would recommend their treatment to others. This
is in line with findings from a previous study in
91 chronic smokers, where bupropion SR was
found to ameliorate selected nicotine withdrawal
effects (difficulty in concentrating, irritability and
depression).25
We hypothesised that as the current study
examined persistent smokers with serious disease,
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there may be an increase in the rate of adverse
events and in vital sign abnormalities (particularly
blood pressure and pulse rate) compared with pre-
vious studies of general smoking populations. How-
ever, bupropion SR was well tolerated with a safety
profile comparable to that seen previously and with
few discontinuations due to adverse events. Impor-
tantly, although bupropion is a norepinephrine
reuptake inhibitor its administration had no impact
on vital signs such as blood pressure. There were no
cases of seizure or severe hypersensitivity reactions
in this study. Each of these adverse events has
previously been reported to occur in about 0.1% of
subjects treated with bupropion SR,26,27 thus, less
than one case of each would be expected in the
current study.
In this study we have shown that treatment with
bupropion SR can significantly improve rates of
smoking abstinence over placebo in a population of
smokers with stable CVD who had previously been
recalcitrant to quitting. The safety profile and posi-
tive patient responses further suggest that bupro-
pion SR is a valuable medication for smoking
cessation in smokers with CVD.
Acknowledgements
We gratefully acknowledge the assistance of the
Principal Investigators in the Zyban® Cardiovascular
Study (ZYB40014) team:
Australia: Krum H., McKiernan M., Silagy C.,
Stuckey B. Austria: Irsigler K., Pilger E., Vetter
N. Germany: Fritz H., Kaspari S., Krause H.,
Lindemann L., von Olshausen K. Greece: Chalkidis
C., Manolis A., Vardas P. Hungary: Farsang C.,
Hanko´czy J. Netherlands: Deckers J., Meyboom-de-
Jong B., van Spiegel P. New Zealand: Kerr D., Rea
H. Norway: Aaserud E., Tonstad S. Switzerland:
Perruchoud A. UK: Hajek P., Lewis K., Murphy M.
We would also like to thank Professor P. Hajek,
at St. Bartholomew's and the Royal London School
of Medicine (London, UK) who developed the moti-
vational support programme utilised in this study.
This study was supported by an educational grant
from GlaxoSmithKline.
In addition to Dr Tonstad, several other indi-
viduals took part in designing the study. Analyses
were performed by GlaxoSmithKline, however, all
data were available to the authors for analysis. The
data interpretation, report writing, and decision to
submit the paper have involved all the authors,
including those employed by GlaxoSmithKline. Drs
Tonstad, Manolis, Perruchoud and Van Spiegel have
all received honoraria from GlaxoSmithKline for
giving lectures.
References
1. Parish S, Collins R, Peto R et al. Cigarette smoking, tar
yields, and non-fatal myocardial infarction: 14,000 cases
and 32,000 controls in the United Kingdom. The Inter-
national Studies of Infarct Survival (ISIS) Collaborators. BMJ
1995;311:471–7.
2. McGinnis JM, Foege WH. Actual causes of death in the
United States. J Am Med Assoc 1993;270:2207–12.
3. The World Health Organization. The World Health Report;
1999.
4. Daly LE, Mulcahy R, Graham IM et al. Long term effect on
mortality of stopping smoking after unstable angina and
myocardial infarction. Br Med J (Clin Res Ed) 1983;
287:324–6.
5. Rosenberg L, Kaufman DW, Helmrich SP et al. The risk of
myocardial infarction after quitting smoking in men under
55 years of age. N Engl J Med 1985;313:1511–4.
6. Rosenberg L, Palmer JR, Shapiro S. Decline in the risk
of myocardial infarction among women who stop smoking.
N Engl J Med 1990;322:213–7.
7. Dobson AJ, Alexander HM, Heller RF et al. How soon after
quitting smoking does risk of heart attack decline?
J Clin Epidemiol 1991;44:1247–53.
8. Joint British recommendations on prevention of coronary
heart disease in clinical practice. British Cardiac Society,
British Hyperlipidaemia Association, British Hypertension
Society, endorsed by the British Diabetic Association. Heart
1998;80(Suppl 2):1–29.
9. Hurt RD, Sachs DP, Glover ED et al. A comparison of
sustained-release bupropion and placebo for smoking
cessation. N Engl J Med 1997;337:1195–202.
10. Jorenby DE, Leischow SJ, Nides MA et al. A controlled
clinical trial of sustained-release bupropion, a nicotine
patch, or both for smoking cessation. N Engl J Med 1999;
340:685–91.
11. Tashkin D, Kanner R, Bailey W et al. Smoking cessation in
patients with chronic obstructive pulmonary disease: a
double-blind, placebo-controlled, randomised trial. Lancet
2001;357:1571–5.
12. Tonstad S, Aaserud E, Hjalmarson A et al. on behalf of the
Zyban Study Group. Bupropion SR is an effective and well-
tolerated aid to smoking cessation in a general smoking
population: an international study (ZYB40017). Poster
presentation at SRNT Third European Conference; 2001,
Sept 20–22; Paris, France.
13. Hays JT, Hurt RD, Rigotti NA et al. Sustained-release bupro-
pion for pharmacologic relapse prevention after smoking
cessation: a randomised controlled trial. Ann Intern Med
2001;135:423–33.
14. West R, McNeill A, Raw M. Smoking cessation guidelines for
health professionals: an update. Thorax 2000;55:987–99.
15. Fiore MC. US public health service clinical practice guide-
line: treating tobacco use and dependence. Respir Care
2000;45:1200–62.
16. Lancaster T, Stead L, Silagy C et al. Effectiveness of inter-
ventions to help people stop smoking: findings from the
Cochrane Library. BMJ 2000;321:355–8.
17. Guidance on the use of nicotine replacement therapy (NRT)
and bupropion for smoking cessation. Technology appraisal
guidance—no. 39. London: National Institute for Clinical
Excellence; March 2002.
18. Smoking withdrawal in hospital patients: factors associated
with outcome. Subcommittee of the Research Committee of
the British Thoracic Society. Thorax 1984;39:651–6.
954 S. Tonstad et al.
19. Hayford KE, Patten CA, Rummans TA et al. Efficacy of
bupropion for smoking cessation in smokers with a former
history of major depression or alcoholism. Br J Psychiatry
1999;174:173–8.
20. Heatherton TF, Kozlowski LT, Frecker RC et al. The
Fagerstro¨m Test for Nicotine Dependence: a revision of the
Fagerstro¨m Tolerance Questionnaire. Br J Addict 1991;
86:1119–27.
21. Fagerstro¨m KO, Heatherton TF, Kozlowski LT. Nicotine
addiction and its assessment. Ear Nose Throat J 1990;
69:763–8.
22. Gart J. Point and interval estimation of the common odds
ratio in the combination of 2 × 2 tables with fixed marginals.
Biometrika 1970;57:471–5.
23. Cox DR. A simple example of a comparison involving quantal
data. Biometrika 1966;53:215–20.
24. Jeffery RW, Hennrikus DJ, Lando HA et al. Reconciling
conflicting findings regarding postcessation weight concerns
and success in smoking cessation. Health Psychol 2000;
19:242–6.
25. Shiffman S, Johnstone JA, Khayrallah M et al. The effect
of bupropion on nicotine craving and withdrawal.
Psychopharmacology 2000;148:33–40.
26. Dunner DL, Zisook S, Billow AA et al. A prospective safety
surveillance study for buproion sustained-realease in the
treatment of depression. J Clin Psychiatry 1998;59:
366–73.
27. Ferry L, Johnston A. Efficacy and safety of buproion SR
for smoking cessation: data from clinical trials and
5 years of postmarketing experience. 3rd European
Congress on Tobacco or Health; 2002 June 19–22; Warsaw,
Poland.
Bupropion SR in smokers with cardiovascular disease 955
